Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: Possible application for compensatory anti-inflammatory response syndrome

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 895-901

  Yamaguchi, Yoshiyuki ^a   Hihara, Jun ^a   Hironaka, Katsuji ^a   Ohshita, Akiko ^a   Okita, Riki ^a   Okawaki, Makoto ^a   Matsuura, Kazuo ^a   Nagamine, Ichiro ^a   Ikeda, Takuhiro ^a   Ohara, Masahiro ^a   Hamai, Yoichi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Compensatory anti inflammatory response syndrome; Esophageal cancer; Lymphokine activated killer cells; Postoperative immunosuppression

Indexed keywords

CONCANAVALIN A; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; AGED; ARTICLE; BLOOD; CELL COUNT; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METHODOLOGY; MIDDLE AGED; MIXED LYMPHOCYTE CULTURE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME; TRANSPLANTATION;

AGED; CELL COUNT; CONCANAVALIN A; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-10; INTERLEUKIN-6; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS;

EID: 33746468263     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.895     Document Type: Article

References (27)

1. Dinarello CA: Proinflammatory cytokines. Chest 118: 503-508 2000.
2. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Crit Care Med 20: 864-874, 1992.
3. Bone RC: Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 24: 1125-1128, 1996.
4. Hensler T, Sauerland S, Bouillon B, Raum M, Rixen D, Helling HJ, Andermahr J and Neugebauer EA: Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6, and interleukin-10 and polymorphonuclear neutrophil elastase. J Trauma 52: 962-970, 2002. (Pubitemid 34534485)
5. Keel M and Trentz O: Pathophysiology of polytrauma. Injury 36: 691-709, 2005. (Pubitemid 40732303)
6. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM and Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. Soluble TNF Recetpor Study Group. N Eng J Med 334: 1697-1702, 1996. (Pubitemid 26193621)
7. Lyons A, Goebel A, Mannick JA and Lederer JA: Protective effects of early interleukin 10 antagonism on injury-induced immune dysfunction. Arch Surg 134: 1317-1323, 1999.
8. Gross-Weege W, Weiss M, Schneider M, Wenning M, Harms B, Dumon K, Ohmann C and Roher HD: Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med 23: 16-22, 1997. (Pubitemid 27067891)
9. Fanning NF, Kell MR, Shorten GD, Kirwan WO, Bouchier-Hayes D, Cotter TG and Redmond HP: Circulating granulocyte macrophage colony-stimulating factor in plasma of patients with the systemic inflammatory response syndrome delays neutrophil apoptosis through inhibition of spontaneous reactive oxygen species generation. Shock 11: 167-174, 1999.
10. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R and Volk HD: Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome: a new approach: proof of principle. Arch Intern Med 157: 389-393, 1997. (Pubitemid 27089964)
11. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA and Rodrick ML: Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 222: 482-490, 1995.
12. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313: 1485-1492, 1985. (Pubitemid 16212345)
13. Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shuimizu K, Minami K, Hihara J, Miyahara E and Toge T: Adoptive immunotherapy of cancer using activated autologous lymphocytes: current status and new strategies. Human Cell 16: 183-189, 2003.
14. Ueda Y, Yamagishi H, Tanioka Y, Fujiwara H, Fuji N, Itoh T, Fujiki H, Yoshimura T and Oka T: Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 46: 1274-1279, 1999. (Pubitemid 29241644)
15. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
16. Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or non-curative resection of primary lung carcinoma. Cancer 80: 42-49, 1997. (Pubitemid 27270918)
17. Toge T, Hamamoto S, Itagaki E, Yajima K, Tanada M, Nakane H, Kohno H, Nakanishi K and Hattori T: Concanavalin A-induced and spontaneous suppressor cell activities in peripheral blood lymphocytes and spleen cells from gastric cancer patients. Cancer 52: 1624-1631, 1983. (Pubitemid 13018282)
18. Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, Illingworth JM, Perren TJ, Selby PJ and Whicher JT: The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 102: 217-223, 1995.
19. Shibata Y, Tamura K and Ishida N: Cultured human monocytes, granulocytes and a monoblastoid cell line (THP-1) synthesize and secrete immunosuppressive acidic protein (a type of alpha 1-acid glycoprotein). Microbiol Immunol 28: 99-111, 1984. (Pubitemid 14158487)
20. Yamaguchi Y, Miyahara E, Funakoshi M, Takashima I, Kawami H, Sato Y and Toge T: Modulation of CD4 antigen expression on the lymphocyte surface by immunosuppressive acidic protein in cancer patients. Oncology 52: 1-6, 1995.
21. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of single mechanism of self-tolerance causes various autoimmune disease. J Immunol 155: 1151-1164, 1995.
22. + regulatory T cells control innate immune reactivity after injury. J Immunol 174: 2957-2963, 2005.
23. Noma K, Yamaguchi Y, Okita R, Matsuura K and Toge T: The spleen plays an immunosuppressive role in patients with gastric cancer: involvement of CD62L+ cells and TGF-beta. Anti-cancer Res 25: 643-649, 2005. (Pubitemid 40470076)
24. - T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149-5153, 2004.
25. Elias JA, Lentz V and Cummings PJ: Transforming growth factor-beta regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts. J Immunol 146: 3437-3443, 1991.
26. Damle NK, Doyle LV and Bradley EC: Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137: 2814-2822, 1986. (Pubitemid 17177784)
27. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K and Kakizoe T: A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 47: 73-78, 1993. (Pubitemid 23179962)